Future Market Insights has revealed a promising trajectory for the Global Gastroesophageal Junction Adenocarcinoma Therapeutics Industry, forecasting an impressive 18% Compound Annual Growth Rate (CAGR) during the period from 2023 to 2033. By 2033, the global market for GEJAC Therapeutics is poised to reach an extraordinary valuation of US$ 34.3 Billion, reflecting a paradigm shift …